Regulatory Roundup: FDA Issues Warning Letters to Six US Medical Spas; and More. - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Regulatory Roundup: FDA Issues Warning Letters to Six US Medical Spas; and More.

ePT--the Electronic Newsletter of Pharmaceutical Technology

Regulatory Roundup

Last week, the US Food and Drug Administration issued Warning Letters to six US medical spas and one Brazilian company for issuing misleading statements online about a medical procedure. The procedure, lipodissolve, involves a series of injections (i.e., phosphatidylcholine, deoxycholate, and other ingredients) and was promoted online as being safe and effective at removing pockets of fat from the body. “FDA is not aware of any credible scientific evidence that supports the effectiveness of any of these substances for fat elimination, and their safety when used alone or in combination is unknown,” said the agency in an press release about the Warning Letters. In addition, the agency has received adverse-event reports from patients using these drugs. The companies that received the Warning Letters were: Monarch Medspa (King of Prussia, PA), Spa 35 (Boise, ID), Medical Cosmetic Enhancements (Chevy Chase, MD), Innovative Directions in Health (Edina, MN), PURE Med Spa (Boca Raton, FL), and All About You Med Spa (Madison, IN). The Brazilian company comprised two websites: zipmed.net and mesoone.com. Read the full Warning Letters.

Last week, Pharmaceutical Technology noted that FDA had published two new guidances for industry based on the Step-4 version of the International Conference on Harmonization’s (ICH) Q4B Annexes 7 and 9. The agency has now published Annex 10 of the same ICH guideline as a guidance for industry. Annex 10 addresses polyacrylamide gel electrophoresis. FDA guidance based on ICH guidelines allow industry to use the US Pharmacopeia, European Pharmacopeia, and Japanese Pharmacopeia interchangeably for the tests described, although FDA can disallow interchangeability at any point.

 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here